Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) was up 3.4% during trading on Monday . The stock traded as high as C$2.60 and last traded at C$2.40. Approximately 6,051 shares traded hands during trading, a decline of 18% from the average daily volume of 7,410 shares. The stock had previously closed at C$2.32.
Eupraxia Pharmaceuticals Trading Up 2.1 %
The firm has a fifty day moving average price of C$2.60 and a 200 day moving average price of C$2.70.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Featured Stories
- Five stocks we like better than Eupraxia Pharmaceuticals
- What Are Growth Stocks and Investing in Them
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Invest in Blue Chip Stocks
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What Does a Stock Split Mean?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.